QNRX
Quoin Pharmaceuticals, Ltd.
Biotechnology
Market Cap$4M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
QNRX vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-75.0%
QNRX vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | QNRX | NVCR |
|---|---|---|
| Industry | Biotechnology | Medical - Instruments & Supplies |
| Market Cap | $4M | $1.92B |
| Revenue (TTM) | $0.00 | $674M |
| Net Income (TTM) | $-15.81B | $-173M |
| Gross Margin | — | 75.2% |
| Operating Margin | — | -27.2% |
| Total Debt | $0.00 | $290M |
| Cash & Equiv. | $3.82B | $103M |
QNRX vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
QNRX
NVCR
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Quoin Pharmaceutica… (QNRX) | 100 | 0.0 | -100.0% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: QNRX vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: QNRX leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. NovoCure Limited is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
QNRX
Quoin Pharmaceuticals, Ltd.
The Income Pick
QNRX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 0.00
- Lower volatility, beta 0.00, current ratio 3.61x
- Beta 0.00, current ratio 3.61x
Best for: income & stability and sleep-well-at-night
NVCR
NovoCure Limited
The Growth Play
NVCR is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 8.3%, EPS growth 21.8%, 3Y rev CAGR 6.8%
- 30.3% 10Y total return vs QNRX's -100.0%
- 8.3% revenue growth vs QNRX's -1.5K%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NVCR | 8.3% revenue growth vs QNRX's -1.5K% |
| Quality / Margins | QNRX | 2.4% margin vs NVCR's -25.7% |
| Stability / Safety | QNRX | Beta 0.00 vs NVCR's 2.20 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | QNRX | +3.7% vs NVCR's +1.1% |
| Efficiency (ROA) | NVCR | -16.5% ROA vs QNRX's -1.2K% |
QNRX vs NVCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNVCRLAGGINGQNRX
QNRXQuoin Pharmaceuticals…
1leads
NVCRNovoCure Limited
2leads
6 Total Categories
CATEGORYLEADERvs QNRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
QNRX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NVCR4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
NVCR5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
QNRX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NVCR and QNRX operate at a comparable scale, with $674M and $0 in trailing revenue.
| Metric | QNRXQuoin Pharmaceuti… | NVCRNovoCure Limited |
|---|---|---|
| RevenueTrailing 12 months | $0 | $674M |
| EBITDAEarnings before interest/tax | -$12M | -$165M |
| Net IncomeAfter-tax profit | -$15.8B | -$173M |
| Free Cash FlowCash after capex | -$16M | -$48M |
| Gross MarginGross profit ÷ Revenue | — | +75.2% |
| Operating MarginEBIT ÷ Revenue | — | -27.2% |
| Net MarginNet income ÷ Revenue | — | -25.7% |
| FCF MarginFCF ÷ Revenue | — | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +72.8% | -100.0% |
QNRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — QNRX and NVCR each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | QNRXQuoin Pharmaceuti… | NVCRNovoCure Limited |
|---|---|---|
| Market CapShares × price | $4M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | -$3.8B | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.92x |
| Price / BookPrice ÷ Book value/share | 0.52x | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — QNRX and NVCR each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
NVCR leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
NVCR delivers a -50.8% return on equity — every $100 of shareholder capital generates $-51 in annual profit, vs $-2722 for QNRX. On the Piotroski fundamental quality scale (0–9), NVCR scores 5/9 vs QNRX's 2/9, reflecting solid financial health.
| Metric | QNRXQuoin Pharmaceuti… | NVCRNovoCure Limited |
|---|---|---|
| ROE (TTM)Return on equity | -2721.7% | -50.8% |
| ROA (TTM)Return on assets | -1229.6% | -16.5% |
| ROICReturn on invested capital | — | -16.4% |
| ROCEReturn on capital employed | -124.5% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | — | 0.85x |
| Net DebtTotal debt minus cash | -$3.8B | $187M |
| Cash & Equiv.Liquid assets | $3.8B | $103M |
| Total DebtShort + long-term debt | $0 | $290M |
| Interest CoverageEBIT ÷ Interest expense | — | -96.80x |
NVCR leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
NVCR leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NVCR five years ago would be worth $875 today (with dividends reinvested), compared to $1 for QNRX. Over the past 12 months, QNRX leads with a +3.7% total return vs NVCR's +1.1%. The 3-year compound annual growth rate (CAGR) favors NVCR at -37.6% vs QNRX's -70.1% — a key indicator of consistent wealth creation.
| Metric | QNRXQuoin Pharmaceuti… | NVCRNovoCure Limited |
|---|---|---|
| YTD ReturnYear-to-date | -54.8% | +28.3% |
| 1-Year ReturnPast 12 months | +3.7% | +1.1% |
| 3-Year ReturnCumulative with dividends | -97.3% | -75.7% |
| 5-Year ReturnCumulative with dividends | -100.0% | -91.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | +30.3% |
| CAGR (3Y)Annualised 3-year return | -70.1% | -37.6% |
NVCR leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — QNRX and NVCR each lead in 1 of 2 comparable metrics.
Risk & Volatility
QNRX is the less volatile stock with a 0.00 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs QNRX's 15.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | QNRXQuoin Pharmaceuti… | NVCRNovoCure Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.00x | 2.20x |
| 52-Week HighHighest price in past year | $41.80 | $20.06 |
| 52-Week LowLowest price in past year | $5.20 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +15.2% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 49.9 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 111K | 1.5M |
Evenly matched — QNRX and NVCR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | QNRXQuoin Pharmaceuti… | NVCRNovoCure Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $33.50 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NVCR leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). QNRX leads in 1 (Income & Cash Flow). 2 tied.
Best OverallNovoCure Limited (NVCR)Leads 2 of 6 categories
Loading custom metrics...
QNRX vs NVCR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is QNRX or NVCR a better buy right now?
Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — QNRX or NVCR?
Over the past 5 years, NovoCure Limited (NVCR) delivered a total return of -91.
3%, compared to -100. 0% for Quoin Pharmaceuticals, Ltd. (QNRX). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus QNRX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — QNRX or NVCR?
By beta (market sensitivity over 5 years), Quoin Pharmaceuticals, Ltd.
(QNRX) is the lower-risk stock at 0. 00β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 1102150% more volatile than QNRX relative to the S&P 500.
04Which is growing faster — QNRX or NVCR?
On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21.
8% year-over-year, compared to -220. 3% for Quoin Pharmaceuticals, Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — QNRX or NVCR?
Quoin Pharmaceuticals, Ltd.
(QNRX) is the more profitable company, earning 0. 0% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QNRX leads at 0. 0% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — QNRX or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is QNRX or NVCR better for a retirement portfolio?
For long-horizon retirement investors, Quoin Pharmaceuticals, Ltd.
(QNRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 00)). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (QNRX: -100. 0%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between QNRX and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.